Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07551635 | SMARCA4/2 Inhibitor for POU2F3-Positive SCLC | PHASE2 | NOT YET_RECRUITING | 20 | — | — | Sep 4, 2026 | Jan 31, 2029 | Apr 27, 2026 | 1 | United States |
ORR is the percentage of participants achieving complete or partial response on treatment based on RECIST v1.1 criteria (Eisenhauer et al Eur J Ca 45:228-247, 2009).
| Arm | Type | Description |
|---|---|---|
| FHD-286 | EXPERIMENTAL | * Baseline visit * Cycle 1 through End of Treatment (21-day cycles) * Days 1 - 21: Predetermined dose of FHD-286 1X daily. Possible dose escalation or based on tolerability. * 30 day follow up post-treatment discontinuation * Annual follow up for up to 5 years. |
| Name | Type | Description |
|---|---|---|
| FHD-286 | DRUG | SMARCA4/2 inhibitor, capsule, taken orally per protocol |
Inclusion Criteria: * Adult age l8 years or older, who have provided written informed consent. * Histologically or cytologically confirmed extensive stage SCLC with documented disease progression or recurrence after prior platinum-based therapy with or without checkpoint inhibitor. * Positive \>50%...